SK Bioscience is speeding up the commercialization of its own COVID-19 vaccine. In particular, it is predicted that the approval of the Novavax vaccine will have a positive effect at a time when the GBP510 is aimed at licensing items in the first half of this year.

On the 12th, the MFDS approved Nuvaxovid PFS, NovaVax's COVID-19 vaccine. The item approval of this vaccine was carried out by SK Bioscience, not Novavax. Novavax handed over the right to sell Novavax vaccines to SK Bioscience in Thailand and Vietnam, including Korea, through an expansion contract with SK Bioscience late last year.

◆Nuvaxovid-GBP510

The pharmaceutical industry believes that this experience